Company history

Japan Tobacco began in 1949 not as a business but as an arm of the state. Under Occupation (GHQ) direction the prewar Monopoly Bureau of the Finance Ministry was broken out into an independent public corporation — the Japan Tobacco & Salt Public Corporation (日本専売公社) — holding the national monopoly on tobacco, salt and camphor. The monopoly right passed intact to the new body, and with it the continuity of a fiscal revenue stream the government was loath to surrender. Employees left the civil service for corporate employment but were denied the right to strike, while budgets and investment plans still required Diet approval — a compromise design that tightly limited managerial discretion in order to keep labour calm.

The corporation bought the entire domestic leaf-tobacco crop at politically negotiated prices, regardless of supply and demand. Its real counterparties were never consumers but the Finance Ministry, the tax authorities and the ruling party’s “tobacco tribe” of Diet members; because tobacco was a stable pillar of tax revenue bound up with the rural vote, reform was deferred for decades. For more than thirty years JT was less a competitor in a market than a vast machine mediating between politics and public finance — stable in the short run, but structurally unable to make the nimble decisions of a private firm. That constraint became the starting point of the privatization debate to come.

In 1984 the Japan Tobacco Inc. Law passed the Diet, and in April 1985 the corporation was reborn as Japan Tobacco Inc. — a joint-stock company whose shares the Finance Minister held in full, to be sold down over time. Incorporation finally loosened the dependence on Diet budget approval and, for the first time, let management reshape the business portfolio at its own discretion; a business-development division was set up the same year to begin lowering the reliance on a single product. The vast distribution network and financial base inherited from the monopoly were a genuine strength — but they came attached to an organization that had never had to compete, now pushed into an open market.

Almost at once three shocks arrived together: the strong yen after the 1985 Plaza Accord, tobacco tax increases, and the 1987 abolition of import tariffs. Foreign majors, treating Japan as a promising growth market, poured money into brand advertising and distribution; the domestic share that had stood at 97.6% in fiscal 1985 fell to 90.2% by fiscal 1987, and President Nagaoka Minoru’s forecast that imports would reach “only about 5%” within five years was quickly overtaken. JT moved into pharmaceuticals and food through the early 1990s, but neither could match tobacco in scale or margin, and in 1993 the adult-male smoking rate slipped below 60% for the first time since surveys began in 1965. Behind a home tobacco business that still threw off cash sat a structural decline that would not reverse — the problem that came to sit at the centre of management.

In May 1999 JT bought RJR Nabisco’s tobacco business outside the United States for $7.2 billion — about $7.8 billion including assumed debt, the largest overseas acquisition ever by a Japanese company at the time. It was not impulsive: JT had passed on an approach in the late 1980s and spent nearly a decade gathering intelligence, cutting its teeth first on the small 1992 purchase of Manchester Tobacco in Britain. The logic was blunt — demand in rich countries had peaked, but would grow in developing markets as incomes rose, so “as long as tobacco is our core, going global is unavoidable.” The deal brought brands and a sales network across more than seventy countries and vaulted JT to third in the world.

In 2007 JT went bigger still, buying Britain’s Gallaher for about ¥2.25 trillion — one of the largest deals in European tobacco — for its strong positions in Russia and Kazakhstan. The first bet had paid off: overseas tobacco operating profit, once mocked as a reckless trillion-yen gamble, reached $567.6M (¥66bn) for the year to March 2006. But the same years demanded relentless restructuring at home. Under the “JT PLAN-V” mid-term plan the company solicited some 4,000 voluntary redundancies in 2003 and closed eight domestic factories in 2005, with further plant closures and another 1,600 job cuts through 2013 — even as it set profit records, earning a reputation as a company that restructures endlessly in order to keep earning.

The portfolio was also being pruned, not only widened. JT had entered food with a 2008 tender offer for Katokichi, but in December 2015 it quit the beverage business, unable to lift returns against the drinks majors despite its own vending network. The same year it agreed to buy the non-US business of Natural American Spirit for about ¥600 billion — the trademarks and nine overseas subsidiaries, deliberately excluding the litigation-exposed US market — a bet on price band and brand character over volume. President Koizumi Mitsuomi’s line was explicit: compete not on unit share but on value, lifting revenue-based share through premium products. Diversify, in short, only where it could win.

JT entered the heated-tobacco market in earnest in 2018, a late follower to Philip Morris International’s IQOS. Newly appointed president Terabatake Masamichi named reduced-risk products the top priority and tilted resources toward them, but catching up cost far more time and money than expected. With the domestic cigarette market shrinking several percent a year, the central question became how fast and how far smokers would actually migrate — and how much to invest in the new category while the old, high-margin one still paid the bills. It was the double bind of thinning a profitable business to feed one that had yet to turn a profit.

In January 2022 JT moved the headquarters of its tobacco business wholesale to Geneva. The Tokyo head office had been built around the domestic business and could not directly read foreign regulation or rivals — a governance friction visible ever since the 1999 RJR purchase. Placing decision-making next to the main overseas markets marked the practical completion of JT’s transformation into a global tobacco company; Tokyo kept oversight of domestic tobacco and the food and pharmaceutical businesses, formalizing a two-tier structure some thirty-seven years after privatization began.

Then the portfolio swung back toward focus. In October 2024 JT bought America’s Vector Group, finally entering the US mainland market it had avoided over litigation risk, and in December 2025 it sold its pharmaceutical business — built up from a 1993 research institute, with Torii Pharmaceutical handed over that September — to Shionogi. The camphor and salt of the monopoly, and the pharma and food added later, were being wound down; resources were pulled back to the earner, tobacco. A company that had once diversified by buying was now concentrating by selling.